← Back to Search

11C-ER176 for Alzheimer's Disease

Phase 1 & 2
Waitlist Available
Led By Patrick Lao, PhD
Research Sponsored by William Charles Kreisl
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Written and oral fluency in English
Age 50 and older
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to one year from baseline
Awards & highlights

Study Summary

This study is evaluating whether a radioactive chemical can be used to measure inflammation in the brain of individuals with Alzheimer's disease.

Eligible Conditions
  • Alzheimer's Disease

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to one year from baseline
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to one year from baseline for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
11C-ER176 Total Distribution Volume
Secondary outcome measures
11C-ER176 Standardized Uptake Value Ratio

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Cognitive impairmentExperimental Treatment2 Interventions
Alzheimer's disease (mild cognitive impairment or mild stage Alzheimer's disease dementia)
Group II: No cognitive impairmentActive Control2 Interventions
Healthy Controls
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
11C-ER176
2018
Completed Phase 2
~10
Florbetaben (18F)
FDA approved

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

William Charles KreislLead Sponsor
6 Previous Clinical Trials
547 Total Patients Enrolled
Columbia UniversityLead Sponsor
1,431 Previous Clinical Trials
2,460,822 Total Patients Enrolled
Patrick Lao, PhDPrincipal InvestigatorColumbia University

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Imaging Inflammation in Alzheimer's Disease With 11C-ER176
Patrick Lao 2018. "Imaging Inflammation in Alzheimer's Disease With 11C-ER176". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03744312.
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top